Premium
LBP‐008: SD1000: 96.4% SVR12 in 1237 patients with hepatitis C genotypes 1, 2, 3, 4 using co‐formulated sofosbuvir/daclatasvir tablets manufactured in Iran – a multicenter phase 3 clinical trial including HIV co‐infected, transplant, and hemodialysis patients
Publication year - 2018
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/jvh.13_12935
Subject(s) - daclatasvir , sofosbuvir , medicine , hepatitis c , clinical trial , hepatitis c virus , gastroenterology , family medicine , virology , ribavirin , virus